GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022
October 26 2022 - 9:00AM
via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a
clinical-stage biotechnology company developing immunotherapies and
vaccines for cancer and infectious diseases, announced today that
it will report third quarter 2022 financial results after the
market close on Wednesday, November 9, 2022.
Following the release, management will host a live conference
call and webcast to provide a general business update and discuss
financial results. Subsequent to management’s prepared remarks,
there will be a Q&A period for analysts and others.
Wednesday, November 9, 2022, 4:30 PM EST
Domestic: 877-269-7756
International: 201-689-7817
Conference ID: 13733113
Webcast: GeoVax Earnings Webcast
A webcast replay of the call will be available via the same link
as the live webcast approximately one hour after the end of the
call through February 9, 2023. A telephonic replay of the call can
be accessed by calling 877-660-6853 (domestic) or 201-612-7415
(international), using access code 13733113. The telephonic replay
will be available until November 23, 2022.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing novel therapies and vaccines for cancers and many of the
world’s most threatening infectious diseases. The company’s lead
program in oncology is a novel oncolytic solid tumor gene-directed
therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical
trial for advanced head and neck cancers. GeoVax’s lead infectious
disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine
targeting high-risk immunocompromised patient populations.
Currently in two Phase 2 clinical trials, GEO-CM04S1 is being
evaluated as a single-dose, COVID-19 vaccine for immunocompromised
patients such as those suffering from hematologic cancers and other
patient populations for whom the current authorized COVID-19
vaccines are insufficient. In addition, GEO-CM04S1 is in a Phase 2
clinical trial evaluating the vaccine as a more robust, durable
COVID-19 booster among healthy patients who previously received the
mRNA vaccines. GeoVax has a leadership team who have driven
significant value creation across multiple life science companies
over the past several decades. For more information, visit our
website: www.geovax.com.
Media Relations Contact: Gina Cestari 6
Degrees 917-797-7904 gcestari@6degreespr.com Investor
Relations Contact:Rich CockrellCG
Capital404-736-3838govx@cg.capital
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Sep 2024 to Oct 2024
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Oct 2023 to Oct 2024